Home › Rheumatoid Arthritis › NCT06397677
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease (MOUNTAIN)
Who can join
Ages 18 to 90 · All sexes
Full eligibility criteria
Inclusion Criteria: * Multidisciplinary diagnosis of RA-ILD based on the 2010 American College of Rheumatology criteria * 18 years of age or older Exclusion Criteria: * Prior medication treatment specifically for RA-ILD * Inability to give informed consent * Pregnant women
About the study
A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression.
The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.
What is being tested
- Research Testing Performed (Laboratory) (genetic)
- Information Collected as Standard of Care (diagnostic test)
- Research Testing Performed (other)
Sponsor: University of Colorado, Denver · Participants: 450 · Started: Jan 22, 2024
Contact the study team
- Haylie Lengel · Phone: 970-376-8303
- Joyce S Lee · Phone: 303-724-6109
Official record on ClinicalTrials.gov — NCT06397677
Locations in the U.S.
| California | University of California San Francisco, San Francisco |
| Colorado | University of Colorado Denver, Aurora |
| Kansas | University of Kansas, Kansas City |
| Michigan | University of Michigan, Ann Arbor |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.